E-resources
Peer reviewed
Open access
-
Gnant, Michael; Fitzal, Florian; Rinnerthaler, Gabriel; Steger, Guenther G; Greil-Ressler, Sigrun; Balic, Marija; Heck, Dietmar; Jakesz, Raimund; Thaler, Josef; Egle, Daniel; Manfreda, Diether; Bjelic-Radisic, Vesna; Wieder, Ursula; Singer, Christian F; Melbinger-Zeinitzer, Elisabeth; Haslbauer, Ferdinand; Sevelda, Paul; Trapl, Harald; Wette, Viktor; Wimmer, Kerstin; Gampenrieder, Simon P; Bartsch, Rupert; Kacerovsky-Strobl, Stephanie; Suppan, Christoph; Brunner, Christine; Deutschmann, Christine; Soelkner, Lidija; Fesl, Christian; Greil, Richard
New England journal of medicine/The New England journal of medicine, 07/2021, Volume: 385, Issue: 5Journal Article
Postmenopausal women with hormone-receptor–positive breast cancer who had received 5 years of adjuvant endocrine therapy were randomly assigned to an additional 2 years or 5 years of therapy with the aromatase inhibitor anastrozole. No between-group differences were noted in disease-free survival, but patients in the 5-year group had more bone fractures.
